Company Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 1999 |
| IPO Date | Apr 14, 2005 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 11,100 |
| CEO | Jacob Leach |
Contact Details
Address: 6340 Sequence Drive San Diego, California 92121 United States | |
| Phone | 858 200 0200 |
| Website | dexcom.com |
Stock Details
| Ticker Symbol | DXCM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001093557 |
| CUSIP Number | 252131107 |
| ISIN Number | US2521311074 |
| Employer ID | 33-0857544 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Jacob Steven Leach | President, Chief Executive Officer and Director |
| Kevin Ronald Sayer | Executive Chairman of the Board |
| Jereme M. Sylvain CPA | Executive Vice President, Chief Financial Officer and Chief Accounting Officer |
| Michael Jon Brown J.D. | Executive Vice President and Chief Legal Officer |
| Sadie M. Stern | Executive Vice President and Chief Human Resources Officer |
| Jon Coleman | Executive Vice President and Chief Commercial Officer |
| Girish Naganathan | Executive Vice President and Chief Technology Officer |
| Sean Christensen | Vice President of Finance and Investor Relations |
| Matthew Dolan | Executive Vice President of Strategy and Corporate Development |
| Donald M. Abbey | Executive Vice President of Global Business Services, Regulatory, Medical and Clinical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2026 | ARS | Filing |
| Apr 15, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 15, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2026 | 144 | Filing |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 16, 2026 | 144 | Filing |
| Mar 2, 2026 | 8-K | Current Report |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 12, 2026 | 10-K | Annual Report |
| Feb 12, 2026 | 8-K | Current Report |